- Research article
- Open Access
ApoER2 expression increases Aβ production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of γ-secretase activity
© Fuentealba et al; licensee BioMed Central Ltd. 2007
- Received: 21 April 2007
- Accepted: 09 July 2007
- Published: 09 July 2007
The generation of the amyloid-β peptide (Aβ) through the proteolytic processing of the amyloid precursor protein (APP) is a central event in the pathogenesis of Alzheimer's disease (AD). Recent studies highlight APP endocytosis and localization to lipid rafts as important events favoring amyloidogenic processing. However, the precise mechanisms underlying these events are poorly understood. ApoER2 is a member of the low density lipoprotein receptor (LDL-R) family exhibiting slow endocytosis rate and a significant association with lipid rafts. Despite the important neurophysiological roles described for ApoER2, little is known regarding how ApoER2 regulates APP trafficking and processing.
Here, we demonstrate that ApoER2 physically interacts and co-localizes with APP. Remarkably, we found that ApoER2 increases cell surface APP levels and APP association with lipid rafts. The increase of cell surface APP requires the presence of ApoER2 cytoplasmic domain and is a result of decreased APP internalization rate. Unexpectedly, ApoER2 expression correlated with a significant increase in Aβ production and reduced levels of APP-CTFs. The increased Aβ production was dependent on the integrity of the NPxY endocytosis motif of ApoER2. We also found that expression of ApoER2 increased APP association with lipid rafts and increased γ-secretase activity, both of which might contribute to increased Aβ production.
These findings show that ApoER2 negatively affects APP internalization. However, ApoER2 expression stimulates Aβ production by shifting the proportion of APP from the non-rafts to the raft membrane domains, thereby promoting β-secretase and γ-secretase mediated amyloidogenic processing and also by incrementing the activity of γ-secretase.
- Lipid Raft
- Amyloid Precursor Protein
- Amyloid Precursor Protein Processing
- ApoER2 Expression
- Amyloidogenic Processing
One of the pathological hallmarks of Alzheimer's disease (AD) is the presence of extracellular deposits of the amyloid beta (Aβ) protein . The Aβ peptide, usually ranging from 40 to 43 amino acids in length, derives from the proteolytic processing of the amyloid precursor protein (APP) and has a central role in AD pathology. Aβ peptide has well-established neurotoxic effects when aggregated into oligomeric and fibrillar states, usually seeded by the amyloid prone Aβ42 species [2, 3] and is also able to interfere with synaptic function, a condition that probably commits neurons to cell death [4–6].
Several cell biology studies on APP metabolism have determined that this membrane protein undergoes two well-compartmentalized processing routes, the amyloidogenic and the non-amyloidogenic . In the amyloidogenic pathway, association of APP to detergent resistant membrane microdomains enriched in cholesterol and glycosphingolipids, also termed lipid rafts, would facilitate the sequential proteolysis of APP by the BACE enzyme (β-secretase) and the γ-secretase complex, generating CTF-β and Aβ plus the signaling related AICD (APP intracellular domain) [8–11]. This is in contrast to APP processing mediated by α-secretase, an enzyme mostly localized at the cell surface and excluded from lipid rafts, whose activity precludes Aβ formation by cutting APP in the middle of the Aβ sequence [12, 13]. Several lines of evidence suggest that part of the amyloidogenic processing of APP occurs in the endocytic pathway. Therefore, it has been proposed that internalization of APP increases the production of Aβ [14, 15]. The tyrosine based endocytosis motif present in the cytoplasmic domain of APP resembles those found in the endocytic receptors low density lipoprotein receptor (LDL-R) and transferrin receptor (TfR), and mediates the rapid internalization of APP through a clathrin mediated-process in coated pits [16, 17]. Mutation of the tetrapeptide YENP within the APP endocytosis motif GYENPTY clearly decreases Aβ generation from cell surface APP [18, 19]. However, a strict requirement of endocytosis for amyloid formation is still a matter of debate, since endocytosis blockage by expression of a mutant form of dynamin or by directly co-patching BACE and APP at the cell surface still allowed Aβ production [20, 21]. Therefore, it is likely that different pools of the secretase complexes regulating Aβ production are present both at the plasma membrane and within the endocytic pathway.
The LDL-R family of lipoprotein receptors is currently composed of 10 members with a diverse array of ligands with different functions, ranging from cellular cholesterol uptake in the liver to cell specification and neuronal positioning during embryogenesis . Several lines of evidence support a role for these receptors in the pathogenesis of AD, including the participation of one of its ligands, the ε4 isoform of apolipoprotein E as major risk factor for AD [23, 24]. LDL-R related proteins (LRPs) share many modular and common structural motifs and usually possess at least one NPxY motif in their relatively short cytoplasmic tail. This motif is critically required for receptor interaction with adaptors proteins and for internalization, with the exception of LRP1, where the endocytosis motif is a YATL . It has been recently demonstrated that several LRPs family members modulate APP processing by affecting different aspects of APP trafficking. For example, LRP1 increases APP endocytosis and Aβ production [26–28], while LRP1B retains APP at the cell surface, preventing it from undergoing amyloidogenic processing . On the other hand, the intracellular trafficking protein SorLA protects cells from generating Aβ by reducing APP trafficking to the cell surface, thereby preventing it from entering the endocytic/amyloidogenic route . Additionally, a particular alternatively spliced isoform of rodent ApoER2 has been demonstrated to interact with APP and decrease Aβ generation upon binding the APP and ApoER2 ligands F-spondin and reelin, respectively [31, 32]. Therefore, regulated subcellular localization of APP by LDL-R family members modulates Aβ production by altering APP distribution and interaction with specific secretases (eg. α-secretases or β-secretases).
Recent experimental and clinical evidence suggest that increased plasma cholesterol levels are an important risk factor for AD [33, 34] Cholesterol lowering drugs decrease Aβ levels and plaque formation in vivo and clinical studies suggest that cholesterol lowering drugs decrease the risk of AD [35–38]. However, data showing the opposite role for cholesterol had also been published (for a review see ), illustrating that this is a still a controversial issue. Cholesterol reducing drugs increase sAPPα secretion with a concomitant decrease in Aβ formation, which might occur by shifting APP localization from lipid rafts to α-secretase-containing regions [13, 21] and/or decreasing the activity of the amyloidogenic enzymes. In fact, cholesterol depletion disrupts β- and γ-secretase association to lipid rafts and causes a decrease in Aβ production [8–10] indicating that lipid rafts are relevant sites for amyloidogenic processing of APP.
ApoER2 is a member of the LDL-R family that is highly expressed in the brain . This receptor has a slower endocytosis rate compared to LRP1 , although its internalization is clathrin-dependent . A significant fraction of ApoER2 is also found in lipid rafts, but the disruption of these membrane microdomains does not affect its endocytic activity . Based on its slow endocytic rate, it was initially proposed that the physiological functions of ApoER2 might be in signal transduction pathways rather than the endocytosis of lipoproteins and other ligands . It is currently known that ApoER2 participates in the reelin signaling pathway during neuronal development [42–44], and recent evidence indicates that it also participates in novel neuronal functions such as maturation of NMDA receptor composition in the hippocampus  and the regulation of long term potentiation [46, 47]. Importantly, it has been determined that the ApoER2 ligand reelin is found in neuritic plaques of transgenic mice overexpressing APP [48–50], suggesting a possible association with AD. It has been shown that one splice variant of the mouse ApoER2 receptor regulates the processing of APP [31, 51]. However, there are no studies addressing whether full length human ApoER2 modulates APP trafficking and consequently its processing. Here, we demonstrate that ApoER2 interacts with APP and increases APP cell surface levels while decreasing APP internalization. However, the increased cell surface APP correlated with increased Aβ production. In addition, ApoER2 expression induced an increase in APP association with lipid rafts and a decrease APP-CTFs levels, which in part could be explained by the increase in γ-secretase activity found in ApoER2 expressing cells. Overall our results indicate that ApoER2 might constitute a novel modulator of APP processing by affecting its endocytic trafficking and the proportion of APP present in lipid rafts, as well as the activity of the γ-secretase complex.
ApoER2 cytoplasmic domain is important for increasing APP at the cell surface
In order to determine whether the molecular determinants for the ApoER2-induced effect on APP trafficking are located in the cytoplasmic domain of the receptor, we analyzed APP cell surface levels in CHO cells expressing the internalization mutants of ApoER2 . We have previously determined that truncation of the entire intracellular domain of ApoER2 (tail less version of ApoER2) promotes its accumulation within intracellular compartments in CHO cells (mostly endoplasmic reticulum) thereby preventing its access to the cell surface. However, a single point mutation (Y/A) in the NPxY sequence of the ApoER2ΔPro isoform abolishes its endocytosis, thereby increasing cell surface ApoER2ΔPro levels. Importantly, both mutated receptors still retain its ability to bind RAP, indicating that alterations imparted to the receptors do not affect their folding and ligand binding . Therefore, we analyzed APP cell-surface levels in CHO-ApoER2-Tailess and CHO-ApoER2ΔPro-NPxA cells. Deletion of the ApoER2 C-terminal domain completely abolished the ApoER2-induced effect on APP subcellular localization. In contrast, the mutation of the NPxY motif within ApoER2ΔPro construct caused an additional slight increase in APP cell surface levels, suggesting that reduced endocytosis of ApoER2 promotes APP accumulation at the cell surface (Fig. 1A, B). These results demonstrate that ApoER2 regulates APP subcellular location and that the cytoplasmic domain of the receptor is important to accomplish this increase in cell surface levels of APP.
ApoER2 interacts with APP695 independently of its cytoplasmic domain
ApoER2 co-localize with APP695 at the plasma membrane and within early endocytic vesicles
ApoER2 diminishes APP695 endocytosis and increases Aβ production
ApoER2 increases APP695 association to lipid rafts but decreases APP-CTF
In this work we assessed the role of ApoER2 in APP trafficking and processing in cells that do not express LRP1, another receptor of the LDL-R family previously described as a modulator of APP processing . Our findings show that ApoER2 decreased APP internalization rate and increased the amount of APP that partitions into lipid rafts, where Aβ is produced. Interestingly, the expression of ApoER2 also significantly increased γ-secretase activity in two different cell types compared to controls. As a net result of these changes, Aβ levels were significantly increased. The effects that ApoER2 has on APP trafficking and processing might be direct, as ApoER2 and APP co-immunoprecipitate and co-localize at the cell surface of neuronal cells and are also found within the same intracellular vesicles upon internalization. Our results show that ApoER2 increases Aβ production despite elevated cell surface APP levels, due to effects on APP association with lipid rafts and γ-secretase activity. This presents a significant and novel mechanism for regulation of APP metabolism by an LDL-R family member.
The catabolism of APP is a well-compartmentalized process. While the predominant non-amyloidogenic pathway occurs mostly if not exclusively at the cell surface, the less frequent amyloidogenic branch occurs either along the biosynthetic pathway during APP delivery to the cell surface or during APP trafficking to endosomes upon internalization from the cell surface . All the LDL-R family proteins that have been demonstrated to interact with APP and affect its processing modify APP trafficking and change Aβ production by modulating the ratio of cell surface/intracellular APP. For example, increased APP localization to intracellular compartments in cells expressing the endocytic LRP1 receptor promotes Aβ generation [27, 28]. On the contrary, expression of the tumor suppressor protein LRP1B, which has a very slow endocytic rate, increases APP levels at the plasma membrane and reduces Aβ production . Another LRP family member, the intracellular sorting related protein SorLA/LR11, interacts with APP in intracellular compartments and modulates its trafficking to the trans-Golgi network, preventing its delivery to the cell surface for subsequent internalization and amyloidogenic processing [30, 65, 66] and its expression is decreased in AD . Ectopic localization of SorLA/LR11 or LRP1 to the cell surface increases cell surface APP with a concomitant decrease in Aβ production, highlighting that the APP amyloidogenic process is facilitated during the cell surface/endocytosis cycles of APP [28, 30]. In a completely opposite scenario, here we demonstrated that human ApoER2 increases APP levels at the cell surface but also increases Aβ levels from endogenous APP in CHO LRP1-null cells. This ApoER2-mediated effect on APP cell surface was also observed with the alternatively spliced ApoER2 isoform lacking the proline rich domain. Interestingly, Aβ42 levels were increased in cells expressing full length ApoER2 but not ApoER2ΔPro, while Aβ40 production was increased in both. It is known that Aβ40 is formed predominantly at the trans-golgi network and endosomes, while Aβ42 is produced in earlier intracellular compartments, mainly intermediate compartments and cis-Golgi cisternae . Although the overall endocytic properties of ApoER2 and ApoER2ΔPro are virtually identical  differences in Aβ42 production might be the result of different APP trafficking routes during the biosynthetic pathway and/or after internalization induced by ApoER2. Alternatively, the association of ApoER2 with adaptor proteins that specifically interact with the proline rich domain, such as PSD-95 or JIP-1/2, might account for these differences [47, 67, 68]. Further experiments are required to address this hypothesis.
In the course of our experiments, similar findings were published in the work by Hoe et al.  showing a physical and functional interaction between ApoER2 and APP695. In that case, however, the secreted protein F-spondin serves as an extracellular link for the interaction of these proteins, which results in increased cell surface APP levels but decreased Aβ levels. Two possible explanations for the discrepancies between these data and those presented here are (i) the different ApoER2 splice variant isoforms used and (ii) the different LRP1 status of the cell lines utilized. In the work by Hoe et al. , they utilized a mouse version of ApoER2 lacking the entire exon 5 coding for repeats 4 to 6 in the ligand binding domain, the main alternatively spliced isoform found in mouse . In the present study, we used the full length ApoER2 version containing all 15 exons encoding the extracellular domain . It is worth mentioning that ApoER2 isoforms lacking repeats 4 to 6 affected activated α2 M but not β-VLDL binding to ApoER2 [71, 72] suggesting that this domain may play a role in binding APP. Although we can not rule out that F-spondin might also increase human full-length ApoER2 interaction with APP and decrease Aβ secretion, this domain may be important for differential binding to other ligands required for the ApoER2-APP functional interaction to modulate Aβ production. Importantly, two additional isoforms of human ApoER2 lacking repeats number four to six and four to seven in the ligand binding domain are also expressed in the brain [70–72] but nothing is known about the regulation of these isoforms during aging or in AD. On the other hand, in our studies we also used two cell lines that lack LRP1 which increases Aβ production but also directly binds and internalizes Aβ . The CHO LRP1-null cells we used here were previously used for assessing the effect of LRP1 mutants on APP processing [27, 28] and in the N2a cells, we did not inmunodetect LRPs or RAP binding activity . Therefore, and in contrast to the experimental system used before , in our study, we were able to dissect these possible LRP1 mediated-events from the effect induced by ApoER2 expression alone.
Early biochemical assays utilizing cell surface radioiodination and endocytosis inhibition by potassium depletion highlighted the importance of APP endocytosis in Aβ production , and subsequent evidence with APP mutants clearly defined molecular determinants required for clathrin-mediated endocytosis of APP and Aβ production [19, 27]. Our results show that ApoER2 decreases endocytosis of APP but surprisingly, increases Aβ production. Recent evidence indicates that APP can also be processed at the cell surface. Endocytosis inhibition by expression of the dominant negative Dynamin-1 protein, DynK44A, increased both Aβ and p3 secretion in HeLa cells . However, the same mutant decreased Aβ secretion in HEK293 stably expressing APP695 . It has been reported that PS1 can be delivered along with Nicastrin to the plasma membrane in a functional complex, where it might proteolyse Notch, Erb4, E-cadherin and APP at the γ-secretase cleavage site . Interestingly, exciting results have been published by the work of Ehehalt et al.  showing that, despite APP endocytosis is required for Aβ production, co-patching of BACE and APP at cell surface lipid rafts bypasses the detrimental effect of APP endocytosis inhibition on amyloidogenic processing arguing that cell surface Aβ production can take place in particular conditions within surface lipid rafts. In our work, we demonstrated that ApoER2 increased the amount of APP fractionating into lipid rafts. Therefore, an increased amyloidogenic processing of APP at plasma membrane lipid rafts might explain the effects induced by ApoER2 (i.e. increased association to lipid rafts and decreased endocytosis rate) and reconcile the increased Aβ production and decreased APP internalization we have observed. Consistent with this notion, LRP1 has been recently recognized as a BACE substrate and both LRP1 and BACE interact at the cell surface , suggesting that other LDL-R family members, including ApoER2, might also be processed by BACE along with the interacting protein APP. As lipid rafts are also located to intracellular compartments (early endosomes, TGN and recycling vesicles ), we can not rule out however that APP that is slowly endocytosed by interaction with ApoER2 expression might routed via clathrin-dependent endocytosis to a lipid raft enriched intracellular compartment for amyloidogenic processing where ApoER2, BACE and the γ-secretase complex have been detected [11, 14, 41, 77–79].
In addition to the increase in APP present in lipid rafts, our results also show a new and interesting effect of ApoER2 expression on the γ-secretase activity. The novel results support the possibility that the increased Aβ levels might also result from increased γ-secretase activity induced by ApoER2 within intracellular compartments. Supporting this model, recently published evidence by Pei and colleagues showed that, β-adrenergic receptor activation induces PS1 endocytosis through a clathrin-mediated process and increases Aβ production . Therefore, an ApoER2-induced delivery of APP to lipid rafts and an increase in γ-secretase activity might also provide the basis of the increased Aβ production by ApoER2 we have observed. Despite our results linking ApoER2 expression with APP-CTFs do not suggest an induction in β-secretase activity, we cannot discard that ApoER2 expression also modifies this proteolytic activity.
Cholesterol positively regulates γ-secretase and Aβ selectively regulates key enzymes for cholesterol metabolism . On the other hand, the raft associated ApoER2 is also a γ-secretase substrate that is proteolytically processed upon apoE binding [31, 81]. Therefore we suggest that neuronal ApoER2 would have a physiological role in APP processing and function, which could be functionally connected to the neuronal lipid homeostasis. Deregulation of a concerted APP/ApoER2 processing might play a role in the pathogenesis of Alzheimer's disease.
Cell lines and cell tissue culturing
Parental CHO LRP-1 null cells were grown in F12HAM/10%FBS supplemented with 100 U Penicillin, 1 U Streptomycin and 5 μg/mL Plasmocin. The ApoER2-HA, ApoER2-ΔPro-HA, ApoER2-ΔPro-NPXA-HA and ApoER2Tless-HA-expressing CHO LRP1-null cells have been previously described  and were grown in the presence of 400 μg/mL G418. Parental N2a were grown in DMEM/7.5% FBS supplemented with 100 U Penicillin, 1 U Streptomycin and 5 μg/mL Plasmocin. ApoER2-HA and ApoER2-Tless-HA-expressing N2a cells  were maintained in growing medium supplemented with 400 μg/mL G418. CHO and N2a cells were transfected using Lipofectamine2000 and different amount of plasmid as noted. For control experiments, total DNA was kept constant by including empty pcDNA3 vector in the transfection mixture. Three h after the addition of the DNA-liposome complexes, the cells were washed with PBS and grown overnight in serum-containing media without antibiotics.
Determination of cell surface APP levels by FACS in CHO LRP-1 null clones
Cells (4 × 106) were plated and grown overnight in 100 mm Petri dishes. Cells were washed with PBS and incubated at 37°C in 3 mL PBS-EDTA 1 mM for 5 min. After the addition of 3 mL complete medium, cells were mechanically detached and collected (40% or 60% of the total) by centrifugation at 700 × g for 5 min in a 15 mL conical tube. The smaller pellet was dissolved in 160 μL PFN (1.5% heat-inactivated FBS, 0.1% NaN3 in PBS) and kept on ice. The remaining cells were resuspended in 160 μL PFN-saponin 0.05% and gently mixed at 4°C for 30 min. Permeabilized cells were similarly collected by centrifugation at 4°C for 10 min and resuspended in 160 μL PFN. Permeabilized and non-permeabilized cells were then equally divided to two microcentrifuge tubes, and 50 μL PFN (control samples) or 50 μL PFN containing 50 ng/μL of anti-APP (6E10, Signet, previously used to detect endogenous APP from CHO cells, ) were added. After gently rocking the tubes at 4°C for 60 min, cells were washed twice with 800 μL PFN or PFN-saponin 0.05%, respectively and resuspended in 50 μL PFN or 50 μL PFN-saponin 0.05% containing 20 μg/mL PE-conjugated donkey anti-mouse IgG (Molecular Probes), respectively. After 40 min secondary antibody incubation at 4°C, cells were similarly washed and resuspended in 300 μL PFN for FACS determinations in a FACScalibur cytometer (Beckton & Dickinson). Surface and total APP fluorescence was represented as the geometric mean of fluorescence intensity from non-permeabilized and permeabilized cells, respectively, after the subtraction of the corresponding blank controls. Results are plotted as % of pcDNA3 control.
ApoER2 and APP co-immunoprecipitation in N2a cells
4 × 106 cells of ApoER2-HA or ApoER2-Tless-HA-expressing N2a cells were grown overnight in 100 mm Petri dishes. Cells were washed twice with PBS and transfected with 30 μg of APP695-Myc plasmid  using Lipofectamine2000. 48 h after transfection, the cells were washed twice with PBS and lysed 30 min at 4–10°C in 500 μL Buffer HUNT (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 1% NP40, 0.5% TX-100, 50 mM NaF) supplemented with 2 mM PMSF and 2× protease inhibitors cocktail. After debris removal by centrifugation, cell lysates were precleared with 20 μL agarose-protein A/G (Pierce) for 30 min at 4°C and then incubated for 2 h at 4°C with 5 μg anti-Myc (clone 9E10, Roche) with gentle rocking. 40 μL agarose-protein A/G (Pierce) was then added, and the mixtures were incubated for 1.5 h at 4°C with gentle rocking. Beads were washed three times with 1 mL Buffer HUNT supplemented with 1 mM PMSF, boiled in 30 μL reducing Laemli Buffer and 7.5% SDS-PAGE was performed. Anti-V5 (Invitrogen) was used as a non-related antibody and mock transfected ApoER2-HA-expressing cells or APP695-Myc only expressing cells were used as controls. For the in vivo requirement experiment, parental N2a cells were analogously transfected in a 60 mm plate and equivalent HUNT lysates from APP-transfected and ApoER2-HA-expressing cells were combined and the standard protocol was followed.
Colocalization analysis in primary rat hippocampal and cortical neurons
Hippocampal and cortical neurons were obtained and cultured as described . Dissociated cells were plated on glass-coverslips coated with 1 mg/ml poly-L-lysine in medium containing 10% horse serum (Invitrogen). After 3 hr, the medium was supplemented with N2 (Invitrogen) . Cells were transiently transfected on day 7 with plasmids encoding APP695-myc and ApoER2-HA using LipofectAMINE 2000. After 18 h, neurons were fixed with 4% PFA and 4% sucrose for 20 min at 37°C, and processed for immunofluorescence as described previously . For cell surface staining, incubation with primary or secondary antibodies was performed before permeabilization with detergents (saponin). Endogenous detection was assessed in hippocampal neurons using anti-APP (6E10, Signet) and anti C-terminal ApoER2 antibodies. Stained cells were analyzed with an inverted microscope (Leica, DM2000) equipped with epifluorescence filters and photographed using a 100× objective. Alternatively, a Zeiss laser scanning confocal microscope was used to collect X-Y sections in 0.45 μm using a 60× objective.
Co-endocytosis of ApoER2-HA and APP695-Myc in N2a cells
N2a cells (8 × 105) were plated in 35 mm Petri dishes and grown overnight. Cells were washed twice with PBS and transfected with plasmids encoding APP 695-Myc (4.5 μg), ApoER2-HA (1.75 μg) and RAP (1.75 μg). After 24 h, the cells were tripsinized and grown in 6 × 10 mm coverslips for an additional day. The cells were chilled on ice for 30 min, washed twice with ice-cold PBS and incubated with 30 μL Binding Buffer (2% BSA in DMEM) containing 1 μg/mL chicken anti-Myc (AB3252, Chemicon) and 1:30 dilution of an anti-HA hybridoma supernatant (Clone 12CA5) for 90 min at 4°C. After washing away excess antibody with PBS, the cells were incubated with 1 mL pre-warmed Binding Buffer for the indicated times at 37°C. Endocytosis was immediately stopped by quickly washing the cells with ice-cold PBS and incubating in 600 μL PFA 2% for 20 min. The cells were permeabilizaed in PBS/saponin 0.2% for 10 min and nonspecific binding sites were blocked with PBS/gelatin 0.2% for 1 h. A mixture of 2 μg/mL donkey anti-mouse Alexa 488 (Molecular Probes) and donkey anti-chicken Alexa 596 (Molecular Probes) secondary antibodies in PBS/gelatin 0.2% was added for 30 min at 37°C and the covers were mounted with DABCO and analyzed either by indirect immunofluorescence with Leica microscope or by confocal microscopy. As a control, cells transfected with 8 μg of pcDNA3 were similarly processed.
Preparation and radioiodination of Diferric transferrin and anti-HA
Diferric transferrin (diFeTf) was prepared from apotransferrin (apoTf) as described previously  with some modifications. 87.5 μL of 10 mg/mL human apoTf in 0.1 M Hepes-KOH pH 7.4 were combined with 3.5 μL of 5 mM Fe(NTA)2. After adding 109 μL of 1 M NaHCO3, the mixture was incubated 30 min at 37°C, and full saturation of apoTf with Fe was monitored by an Abs465/280 ratio of 0.044. Routinely, diFeTf was obtained at 90% saturation. The anti-HA antibody was purified as previously described and eluted in PBS . 25–50 μg of protein was iodinated in 10 mM sodium phosphate buffer pH 7.5 in a total reaction volume of 100 μL with 1–2 mCi Na [125I] by using IODOGEN(Pierce)-treated tubes. After 10 min incubation at room temperature, free iodine was removed by passing the mixture through a PD-10 desalting column (GE healthcare) and iodinated proteins were recovered as one mL eluted fractions. Specific activities of radioligands usually ranged from 30,000 to 50,000 cpm/ng and were stored at 4°C until use.
Radioligand endocytosis in transfected CHO LRP-1 null cells
4 × 106 cells were plated in 100 mm Petri dishes and grown overnight. Cells were washed twice with PBS and transfected with a mixture of plasmids containing 20 μg APP695-HA , 5 μg RAP and ranging from 5 to 20 μg ApoER2 as noted using Lipofectamine 2000. Total DNA was kept constant by including empty pcDNA3 vector where needed. 24 h after transfection, the cells were split into 15 wells of a single column of five 12-well multiplates for the endocytosis assay, as well as 2 wells for Western blot analysis. After an additional 24 hours of culture, the cells were chilled on ice for 30 min, washed twice with ice cold Binding Buffer (0.6% BSA in F12HAM) and incubated 1 h at 4°C with 500 μL Binding Buffer containing 1 nM 125I-anti-HA. After eliminating unbound antibody with two cold Binding Buffer washes, the cells were incubated with 1 mL pre-warmed Binding Buffer and incubated for indicated times at 37°C. Endocytosis was stopped by immediately placing the plate on ice and adding 1 mL cold Stop Strip solution (0.2 M acetic acid, 100 mM NaCl, pH 2.6). Cell surface radioligands were detached from cells twice by incubating the cells in 1 mL Stop Strip for 10 min at 4°C, and internalized radioligands were then recovered by lysing cells in 1 mL Low SDS Buffer (62.5 mM Tris-HCl, 0.2% SDS, 10% glycerol, pH 6.8). Acid labile and endocytosed fractions were counted in a γ-counter and plotted as % internalized-to-total radioactivity ratio versus time. As a specificity control for the antibody, radioactivity measurements were corrected by subtracting the corresponding background radioactivity obtained from similarly processed, control cells. The time at which 50% internalization occurs was referred as the internalization half-time and is inversely related to the endocytosis rate. The same protocol was used for diFeTf endocytosis, except that cells were pre-incubated for 2 h with Binding Buffer at 32°C for maximal recovery of TfR at the cell surface prior to binding of 125I-diFeTf, 5 nM.
Verification of protein expression levels by Western blot
Overnight cultures were scraped in lysis buffer (PBS containing 1% TX-100) supplemented with 1 mM PMSF and a protease inhibitor cocktail for 30 min at 4°C. After nuclei and debris removal by centrifugation, proteins were quantified and 30 μg proteins were subjected to 10% SDS-PAGE and transferred to PVDF membranes. Lysates from gradients were directly used for quantification and Western blotting. In the case of PS1 determination cell extracts were prepared in CHAPSO buffer (50 mM Tris-HCl, 2 mM EDTA, protease inhibitors (Roche), 0.25% CHAPSO pH 6.8). PVDF membranes were blocked with PBS/5% low fat milk and incubated O/N with PBS/5% low fat milk supplemented with the indicated antibody and 0.05% Tween 20 for anti-APP (CT695, Zymed; 1:500), anti-HA (mouse hybridoma supernatant; 1:100), anti-TfR (H68.4, Zymed; 1:1,000), anti-PS1 (1:5,000),  anti-actin (MAB1501R, Chemicon; 1:4,000); or 0.1% Tween 20 for anti-ApoER2 antiserum (1:3,000) at 4°C in a roller. After 3 washes, the membranes were incubated 3 h at room temperature in a roller with HRP coupled anti-mouse IgG antibody (Sigma; 1:5,000) or HRP coupled anti-rabbit HRP (Sigma; 1:10,000). After 4 washes, the membranes were incubated with 10 mL enhanced chemiluminescence reagent and low or high sensitivity films were appropriately used. Quantification of bands was performed using the MATRIX (Quantavision) software.
Aβ40 and Aβ42 determinations
CHO LRP-1 null stable clones (1 × 105 cells) were plated in 35 mm Petri dishes and grown for 48 h. After washing the cells twice with PBS, the cells were grown in 800 μL F12HAM/1%FBS supplemented with antibiotics and 400 μg/mL G418 for additional 48 h. Conditioned media were collected, centrifuged at 20,000 × g for 5 min at 4°C and Aβ40 and Aβ42 concentrations in the cleared conditioned media were determined by sandwich ELISA as previously described . Briefly, serial dilutions of Aβ40 and Aβ42 in F12HAM/1%FBS were prepared for standard curves. 100 μL freshly thawed conditioned media or standard dilutions were subjected to ELISA sandwich using anti-Aβ1–42 (21F12) or anti-Aβ13–28 (266) antibody-covered plates. After overnight incubation at 4°C, wells were extensively washed with guanidine containing buffer, and biotin-conjugated anti-Aβ13–28 (266) antibody or anti-Aβ1–40 (2G3) were added for Aβ40 and Aβ42 detection, respectively. After 90 min incubation at 37°C, avidin-conjugated HRP was added for 90 min, and ELISA was developed with TMB substrate in a SoftMax ELISA machine, reading the plate at 650 nm every 2 min. For normalization, total protein extracts were prepared from the same growing plates by scrapping the cells in lysis buffer (TX-100 1% in PBS) supplemented with 1 mM PMSF and a protease inhibitor cocktail. After nuclei and debris removal by centrifugation, proteins were quantified and Aβ levels were normalized to protein content per well.
Immunodetection of full-length and CTFs of ApoER2 and APP in lipid rafts
4 × 106 cells were grown overnight in 100 mm Petri dishes. Cells were washed twice with PBS and transfected with a mixture of plasmids containing either 20 μg APP, a mixture of 5 μg RAP and 5 μg ApoER2 or both using Lipofectamine 2000. Mock transfected cells were used as a negative control for endogenous APP detection. 24 h after transfection, the cells were split into two 100 mm Petri dishes and treated overnight with 10 μM DAPT or vehicle. The cells were then chilled on ice for 30 min, washed twice with cold PBS, scraped in Lysis Buffer (25 mM MES pH 6.5, 150 mM NaCl, 0.5% Lubrol WX) supplemented with 2 mM PMSF and a 2× protease inhibitors cocktail and incubated on ice for 1 h with periodic vortexing. Lysates were passed through a G27 needle 5 times and debris was removed by centrifugation at 10,000 × g for 3 min at 4°C. 500 μL of lysate were combined with 500 μL of 80% sucrose in MBS (25 mM MES pH 6.5, 150 mM NaCl) and briefly mixed by vortex. Subsequently, 2 mL of 35% sucrose and 2 mL 5% sucrose in MBS were carefully added for discontinuous gradient formation and samples were centrifuged at 130,000 × g for 18 h at 4°C in an AH650 Sorvall Rotor. Twelve 400 μL fractions were recovered from top to bottom, and 300 μL were precipitated by the methanol/chloroform method . Total precipitated proteins were subjected to Tris-Tricine SDS-PAGE for ApoER2- and APP-CTF immunodetection or to 6% SDS-PAGE for full length ApoER2/APP immunodetection by Western blot. In some experiments, gradient fractions were subjected to sucrose content determination and caveolin-1 immunodetection as previously described .
γ-Secretase-mediated peptide cleavage assay
γ-Secretase activity was assayed in vitro using an APP-CTF derived intramolecularly quenched fluorescent peptide according to the manufacturers' instructions (Calbiochem) [60, 63]. Briefly, cellular membranes from N2a and CHO cell were prepared as described  and solubilized in CHAPSO buffer (50 mM Tris-HCl, 2 mM EDTA, protease inhibitors (Roche), 0.25% CHAPSO pH 6.8) followed by incubation at 37°C for different times in 150 μl of assay buffer containing 50 mM Tris-HCl, protease inhibitors (Roche), 2 mM EDTA, 0.25% CHAPSO, pH 6.8 and 8 μM fluorescent APP-CTF derived peptide (Calbiochem). After incubation, the reaction mixture was centrifuged (16,100 × g, 15 min) and the supernatant transferred to a 96 well plate. Fluorescence was measured using a Perkin Elmer Luminescence spectrometer LS50B (excitation/emission at 350/440 nm). Specific γ-secretase activity was determined after subtracting the fluorescence obtained in the presence of DAPT (10 μM). Background fluorescence was calculated by incubating separately 50 μg of CHAPSO-solubilized P2 membranes and 8 μM APP-CTF derived peptide with assay buffer for different times and mixing them just before fluorescence determination.
We would like to thank Dr. Andrés Norambuena and Dr. Isabel Yuseff for their critical advice during the course of the experiments, to Dr. Tulio Nuñez (University of Chile) for providing us with technical support and material for the transferrin endocytosis assay and Dr. Willem Annaert (Katholieke Universiteit Leuven) for providing the PS1 antibody. We thank to Dr. Maria Rosa Bono (University of Chile), Dr. Alex Kalergis and Dr. Leandro Carreño (Pontificia Universidad Católica de Chile) for assistance with FACS experiments and Claudio Retamal (Pontificia Universidad Católica de Chile) for his technical help in the immunofluorescence microscopy experiments. We also thank to Jane Knisely (Washington University in St Louis) for improving final redaction of the manuscript before submission. This work was supported by FIRCA grant TW006456 to GB and MPM, Fondo de Investigación Avanzada en Areas Prioritarias (FONDAP) Grant 13980001, the Millenium Institute for Fundamental and Applied Biology (MIFAB) to MPM and NCI, National Institute on Aging grant R01 AG027924 to G.B., a grant from the Alzheimer's Association to G.B., and a grant from the American Health Assistant Foundation to G.B. Rodrigo Fuentealba was a postdoctoral fellow supported by FONDAP and MIFAB.
- Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001, 81 (2): 741-766.PubMedGoogle Scholar
- Howlett DR, Jennings KH, Lee DC, Clark MS, Brown F, Wetzel R, Wood SJ, Camilleri P, Roberts GW: Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration. 1995, 4 (1): 23-32. 10.1006/neur.1995.0003.View ArticlePubMedGoogle Scholar
- McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T: Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005, 47 (2): 191-199. 10.1016/j.neuron.2005.06.030.PubMed CentralView ArticlePubMedGoogle Scholar
- Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL: Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998, 95 (11): 6448-6453. 10.1073/pnas.95.11.6448.PubMed CentralView ArticlePubMedGoogle Scholar
- Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL: Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci. 2004, 24 (45): 10191-10200. 10.1523/JNEUROSCI.3432-04.2004.View ArticlePubMedGoogle Scholar
- Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE: Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2006, 103 (13): 5161-5166. 10.1073/pnas.0600948103.PubMed CentralView ArticlePubMedGoogle Scholar
- Annaert W, De Strooper B: A cell biological perspective on Alzheimer's disease. Annu Rev Cell Dev Biol. 2002, 18: 25-51. 10.1146/annurev.cellbio.18.020402.142302.View ArticlePubMedGoogle Scholar
- Riddell DR, Christie G, Hussain I, Dingwall C: Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr Biol. 2001, 11 (16): 1288-1293. 10.1016/S0960-9822(01)00394-3.View ArticlePubMedGoogle Scholar
- Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ: Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2003, 100 (20): 11735-11740. 10.1073/pnas.1635130100.PubMed CentralView ArticlePubMedGoogle Scholar
- Vetrivel KS, Cheng H, Kim SH, Chen Y, Barnes NY, Parent AT, Sisodia SS, Thinakaran G: Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J Biol Chem. 2005, 280 (27): 25892-25900. 10.1074/jbc.M503570200.PubMed CentralView ArticlePubMedGoogle Scholar
- Vetrivel KS, Cheng H, Lin W, Sakurai T, Li T, Nukina N, Wong PC, Xu H, Thinakaran G: Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. J Biol Chem. 2004, 279 (43): 44945-44954. 10.1074/jbc.M407986200.PubMed CentralView ArticlePubMedGoogle Scholar
- Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F: Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A. 1999, 96 (7): 3922-3927. 10.1073/pnas.96.7.3922.PubMed CentralView ArticlePubMedGoogle Scholar
- Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc Natl Acad Sci U S A. 2001, 98 (10): 5815-5820. 10.1073/pnas.081612998.PubMed CentralView ArticlePubMedGoogle Scholar
- Kinoshita A, Fukumoto H, Shah T, Whelan CM, Irizarry MC, Hyman BT: Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci. 2003, 116 (Pt 16): 3339-3346. 10.1242/jcs.00643.View ArticlePubMedGoogle Scholar
- Kaether C, Schmitt S, Willem M, Haass C: Amyloid precursor protein and Notch intracellular domains are generated after transport of their precursors to the cell surface. Traffic. 2006, 7 (4): 408-415. 10.1111/j.1600-0854.2006.00396.x.View ArticlePubMedGoogle Scholar
- Koo EH, Squazzo SL, Selkoe DJ, Koo CH: Trafficking of cell-surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody. J Cell Sci. 1996, 109 ( Pt 5): 991-998.Google Scholar
- Yamazaki T, Koo EH, Selkoe DJ: Trafficking of cell-surface amyloid beta-protein precursor. II. Endocytosis, recycling and lysosomal targeting detected by immunolocalization. J Cell Sci. 1996, 109 ( Pt 5): 999-1008.Google Scholar
- Koo EH, Squazzo SL: Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem. 1994, 269 (26): 17386-17389.PubMedGoogle Scholar
- Perez RG, Soriano S, Hayes JD, Ostaszewski B, Xia W, Selkoe DJ, Chen X, Stokin GB, Koo EH: Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. J Biol Chem. 1999, 274 (27): 18851-18856. 10.1074/jbc.274.27.18851.View ArticlePubMedGoogle Scholar
- Chyung JH, Selkoe DJ: Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid beta-protein at the cell surface. J Biol Chem. 2003, 278 (51): 51035-51043. 10.1074/jbc.M304989200.View ArticlePubMedGoogle Scholar
- Ehehalt R, Keller P, Haass C, Thiele C, Simons K: Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol. 2003, 160 (1): 113-123. 10.1083/jcb.200207113.PubMed CentralView ArticlePubMedGoogle Scholar
- May P, Herz J: LDL receptor-related proteins in neurodevelopment. Traffic. 2003, 4 (5): 291-301.View ArticlePubMedGoogle Scholar
- Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD: Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993, 90 (20): 9649-9653. 10.1073/pnas.90.20.9649.PubMed CentralView ArticlePubMedGoogle Scholar
- Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993, 90 (5): 1977-1981. 10.1073/pnas.90.5.1977.PubMed CentralView ArticlePubMedGoogle Scholar
- Li Y, Marzolo MP, van Kerkhof P, Strous GJ, Bu G: The YXXL motif, but not the two NPXY motifs, serves as the dominant endocytosis signal for low density lipoprotein receptor-related protein. J Biol Chem. 2000, 275 (22): 17187-17194. 10.1074/jbc.M000490200.View ArticlePubMedGoogle Scholar
- Ulery PG, Beers J, Mikhailenko I, Tanzi RE, Rebeck GW, Hyman BT, Strickland DK: Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J Biol Chem. 2000, 275 (10): 7410-7415. 10.1074/jbc.275.10.7410.View ArticlePubMedGoogle Scholar
- Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH: The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. Embo J. 2002, 21 (21): 5691-5700. 10.1093/emboj/cdf568.PubMed CentralView ArticlePubMedGoogle Scholar
- Cam JA, Zerbinatti CV, Li Y, Bu G: Rapid endocytosis of the low density lipoprotein receptor-related protein modulates cell surface distribution and processing of the beta-amyloid precursor protein. J Biol Chem. 2005, 280 (15): 15464-15470. 10.1074/jbc.M500613200.View ArticlePubMedGoogle Scholar
- Cam JA, Zerbinatti CV, Knisely JM, Hecimovic S, Li Y, Bu G: The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. J Biol Chem. 2004, 279 (28): 29639-29646. 10.1074/jbc.M313893200.View ArticlePubMedGoogle Scholar
- Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CA, Breiderhoff T, Jansen P, Wu X, Bales KR, Cappai R, Masters CL, Gliemann J, Mufson EJ, Hyman BT, Paul SM, Nykjaer A, Willnow TE: Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2005, 102 (38): 13461-13466. 10.1073/pnas.0503689102.PubMed CentralView ArticlePubMedGoogle Scholar
- Hoe HS, Rebeck GW: Regulation of ApoE receptor proteolysis by ligand binding. Brain Res Mol Brain Res. 2005, 137 (1-2): 31-39. 10.1016/j.molbrainres.2005.02.013.View ArticlePubMedGoogle Scholar
- Hoe HS, Wessner D, Beffert U, Becker AG, Matsuoka Y, Rebeck GW: F-spondin interaction with the apolipoprotein E receptor ApoEr2 affects processing of amyloid precursor protein. Mol Cell Biol. 2005, 25 (21): 9259-9268. 10.1128/MCB.25.21.9259-9268.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Wolozin B: Cholesterol and the biology of Alzheimer's disease. Neuron. 2004, 41 (1): 7-10. 10.1016/S0896-6273(03)00840-7.View ArticlePubMedGoogle Scholar
- Sjogren M, Mielke M, Gustafson D, Zandi P, Skoog I: Cholesterol and Alzheimer's disease--is there a relation?. Mech Ageing Dev. 2006, 127 (2): 138-147. 10.1016/j.mad.2005.09.020.View ArticlePubMedGoogle Scholar
- Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet. 2000, 356 (9242): 1627-1631. 10.1016/S0140-6736(00)03155-X.View ArticlePubMedGoogle Scholar
- Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000, 57 (10): 1439-1443. 10.1001/archneur.57.10.1439.View ArticlePubMedGoogle Scholar
- Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T: Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001, 98 (10): 5856-5861. 10.1073/pnas.081620098.PubMed CentralView ArticlePubMedGoogle Scholar
- Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE: A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001, 8 (5): 890-899. 10.1006/nbdi.2001.0422.View ArticlePubMedGoogle Scholar
- Ledesma MD, Dotti CG: Amyloid excess in Alzheimer's disease: what is cholesterol to be blamed for?. FEBS Lett. 2006, 580 (23): 5525-5532. 10.1016/j.febslet.2006.06.038.View ArticlePubMedGoogle Scholar
- Kim DH, Iijima H, Goto K, Sakai J, Ishii H, Kim HJ, Suzuki H, Kondo H, Saeki S, Yamamoto T: Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J Biol Chem. 1996, 271 (14): 8373-8380. 10.1074/jbc.271.14.8373.View ArticlePubMedGoogle Scholar
- Cuitino L, Matute R, Retamal C, Bu G, Inestrosa NC, Marzolo MP: ApoER2 is endocytosed by a clathrin-mediated process involving the adaptor protein Dab2 independent of its Rafts' association. Traffic. 2005, 6 (9): 820-838. 10.1111/j.1600-0854.2005.00320.x.View ArticlePubMedGoogle Scholar
- D'Arcangelo G, Homayouni R, Keshvara L, Rice DS, Sheldon M, Curran T: Reelin is a ligand for lipoprotein receptors. Neuron. 1999, 24 (2): 471-479. 10.1016/S0896-6273(00)80860-0.View ArticlePubMedGoogle Scholar
- Hiesberger T, Trommsdorff M, Howell BW, Goffinet A, Mumby MC, Cooper JA, Herz J: Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron. 1999, 24 (2): 481-489. 10.1016/S0896-6273(00)80861-2.View ArticlePubMedGoogle Scholar
- Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, Hammer RE, Richardson JA, Herz J: Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell. 1999, 97 (6): 689-701. 10.1016/S0092-8674(00)80782-5.View ArticlePubMedGoogle Scholar
- Sinagra M, Verrier D, Frankova D, Korwek KM, Blahos J, Weeber EJ, Manzoni OJ, Chavis P: Reelin, very-low-density lipoprotein receptor, and apolipoprotein E receptor 2 control somatic NMDA receptor composition during hippocampal maturation in vitro. J Neurosci. 2005, 25 (26): 6127-6136. 10.1523/JNEUROSCI.1757-05.2005.View ArticlePubMedGoogle Scholar
- Weeber EJ, Beffert U, Jones C, Christian JM, Forster E, Sweatt JD, Herz J: Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem. 2002, 277 (42): 39944-39952. 10.1074/jbc.M205147200.View ArticlePubMedGoogle Scholar
- Beffert U, Weeber EJ, Durudas A, Qiu S, Masiulis I, Sweatt JD, Li WP, Adelmann G, Frotscher M, Hammer RE, Herz J: Modulation of synaptic plasticity and memory by Reelin involves differential splicing of the lipoprotein receptor Apoer2. Neuron. 2005, 47 (4): 567-579. 10.1016/j.neuron.2005.07.007.View ArticlePubMedGoogle Scholar
- Wirths O, Multhaup G, Czech C, Blanchard V, Tremp G, Pradier L, Beyreuther K, Bayer TA: Reelin in plaques of beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett. 2001, 316 (3): 145-148. 10.1016/S0304-3940(01)02399-0.View ArticlePubMedGoogle Scholar
- Motoi Y, Itaya M, Mori H, Mizuno Y, Iwasaki T, Hattori H, Haga S, Ikeda K: Apolipoprotein E receptor 2 is involved in neuritic plaque formation in APP sw mice. Neurosci Lett. 2004, 368 (2): 144-147. 10.1016/j.neulet.2004.06.081.View ArticlePubMedGoogle Scholar
- Botella-Lopez A, Burgaya F, Gavin R, Garcia-Ayllon MS, Gomez-Tortosa E, Pena-Casanova J, Urena JM, Del Rio JA, Blesa R, Soriano E, Saez-Valero J: Reelin expression and glycosylation patterns are altered in Alzheimer's disease. Proc Natl Acad Sci U S A. 2006, 103 (14): 5573-5578. 10.1073/pnas.0601279103.PubMed CentralView ArticlePubMedGoogle Scholar
- Hoe HS, Magill LA, Guenette S, Fu Z, Vicini S, Rebeck GW: FE65 interaction with the ApoE receptor ApoEr2. J Biol Chem. 2006, 281 (34): 24521-24530. 10.1074/jbc.M600728200.View ArticlePubMedGoogle Scholar
- Zerbinatti CV, Wahrle SE, Kim H, Cam JA, Bales K, Paul SM, Holtzman DM, Bu G: Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J Biol Chem. 2006, 281 (47): 36180-36186. 10.1074/jbc.M604436200.View ArticlePubMedGoogle Scholar
- Brandes C, Novak S, Stockinger W, Herz J, Schneider WJ, Nimpf J: Avian and murine LR8B and human apolipoprotein E receptor 2: differentially spliced products from corresponding genes. Genomics. 1997, 42 (2): 185-191. 10.1006/geno.1997.4702.View ArticlePubMedGoogle Scholar
- York SJ, Arneson LS, Gregory WT, Dahms NM, Kornfeld S: The rate of internalization of the mannose 6-phosphate/insulin-like growth factor II receptor is enhanced by multivalent ligand binding. J Biol Chem. 1999, 274 (2): 1164-1171. 10.1074/jbc.274.2.1164.View ArticlePubMedGoogle Scholar
- Klausner RD, Van Renswoude J, Ashwell G, Kempf C, Schechter AN, Dean A, Bridges KR: Receptor-mediated endocytosis of transferrin in K562 cells. J Biol Chem. 1983, 258 (8): 4715-4724.PubMedGoogle Scholar
- Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998, 95 (11): 6460-6464. 10.1073/pnas.95.11.6460.PubMed CentralView ArticlePubMedGoogle Scholar
- Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL, Johnson-Wood KL, Kennedy SL, Kholodenko D, Knops JE, Latimer LH, Lee M, Liao Z, Lieberburg IM, Motter RN, Mutter LC, Nietz J, Quinn KP, Sacchi KL, Seubert PA, Shopp GM, Thorsett ED, Tung JS, Wu J, Yang S, Yin CT, Schenk DB, May PC, Altstiel LD, Bender MH, Boggs LN, Britton TC, Clemens JC, Czilli DL, Dieckman-McGinty DK, Droste JJ, Fuson KS, Gitter BD, Hyslop PA, Johnstone EM, Li WY, Little SP, Mabry TE, Miller FD, Audia JE: Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 2001, 76 (1): 173-181. 10.1046/j.1471-4159.2001.00012.x.View ArticlePubMedGoogle Scholar
- Vetrivel KS, Thinakaran G: Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Neurology. 2006, 66 (2 Suppl 1): S69-73.View ArticlePubMedGoogle Scholar
- Chen F, Yang DS, Petanceska S, Yang A, Tandon A, Yu G, Rozmahel R, Ghiso J, Nishimura M, Zhang DM, Kawarai T, Levesque G, Mills J, Levesque L, Song YQ, Rogaeva E, Westaway D, Mount H, Gandy S, St George-Hyslop P, Fraser PE: Carboxyl-terminal fragments of Alzheimer beta-amyloid precursor protein accumulate in restricted and unpredicted intracellular compartments in presenilin 1-deficient cells. J Biol Chem. 2000, 275 (47): 36794-36802. 10.1074/jbc.M006986200.View ArticlePubMedGoogle Scholar
- Farmery MR, Tjernberg LO, Pursglove SE, Bergman A, Winblad B, Naslund J: Partial purification and characterization of gamma-secretase from post-mortem human brain. J Biol Chem. 2003, 278 (27): 24277-24284. 10.1074/jbc.M211992200.View ArticlePubMedGoogle Scholar
- Zou Z, Chung B, Nguyen T, Mentone S, Thomson B, Biemesderfer D: Linking receptor-mediated endocytosis and cell signaling: evidence for regulated intramembrane proteolysis of megalin in proximal tubule. J Biol Chem. 2004, 279 (33): 34302-34310. 10.1074/jbc.M405608200.View ArticlePubMedGoogle Scholar
- Ni Y, Zhao X, Bao G, Zou L, Teng L, Wang Z, Song M, Xiong J, Bai Y, Pei G: Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. Nat Med. 2006, 12 (12): 1390-1396. 10.1038/nm1485.View ArticlePubMedGoogle Scholar
- Urra S, Escudero CA, Ramos P, Lisbona F, Allende E, Covarrubias P, Parraguez JI, Zampieri N, Chao MV, Annaert W, Bronfman FC: TrkA receptor activation by nerve growth factor induces shedding of the p75 neurotrophin receptor followed by endosomal gamma-secretase-mediated release of the p75 intracellular domain. J Biol Chem. 2007, 282 (10): 7606-7615. 10.1074/jbc.M610458200.View ArticlePubMedGoogle Scholar
- Bu G, Cam J, Zerbinatti C: LRP in amyloid-beta production and metabolism. Ann N Y Acad Sci. 2006, 1086: 35-53. 10.1196/annals.1377.005.View ArticlePubMedGoogle Scholar
- Andersen OM, Schmidt V, Spoelgen R, Gliemann J, Behlke J, Galatis D, McKinstry WJ, Parker MW, Masters CL, Hyman BT, Cappai R, Willnow TE: Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry. 2006, 45 (8): 2618-2628. 10.1021/bi052120v.View ArticlePubMedGoogle Scholar
- Spoelgen R, von Arnim CA, Thomas AV, Peltan ID, Koker M, Deng A, Irizarry MC, Andersen OM, Willnow TE, Hyman BT: Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. J Neurosci. 2006, 26 (2): 418-428. 10.1523/JNEUROSCI.3882-05.2006.View ArticlePubMedGoogle Scholar
- Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA, Stockinger W, Nimpf J, Herz J: Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J Biol Chem. 2000, 275 (33): 25616-25624. 10.1074/jbc.M000955200.View ArticlePubMedGoogle Scholar
- Stockinger W, Brandes C, Fasching D, Hermann M, Gotthardt M, Herz J, Schneider WJ, Nimpf J: The reelin receptor ApoER2 recruits JNK-interacting proteins-1 and -2. J Biol Chem. 2000, 275 (33): 25625-25632. 10.1074/jbc.M004119200.View ArticlePubMedGoogle Scholar
- Brandes C, Kahr L, Stockinger W, Hiesberger T, Schneider WJ, Nimpf J: Alternative splicing in the ligand binding domain of mouse ApoE receptor-2 produces receptor variants binding reelin but not alpha 2-macroglobulin. J Biol Chem. 2001, 276 (25): 22160-22169. 10.1074/jbc.M102662200.View ArticlePubMedGoogle Scholar
- Kim DH, Magoori K, Inoue TR, Mao CC, Kim HJ, Suzuki H, Fujita T, Endo Y, Saeki S, Yamamoto TT: Exon/intron organization, chromosome localization, alternative splicing, and transcription units of the human apolipoprotein E receptor 2 gene. J Biol Chem. 1997, 272 (13): 8498-8504. 10.1074/jbc.272.13.8498.View ArticlePubMedGoogle Scholar
- Clatworthy AE, Stockinger W, Christie RH, Schneider WJ, Nimpf J, Hyman BT, Rebeck GW: Expression and alternate splicing of apolipoprotein E receptor 2 in brain. Neuroscience. 1999, 90 (3): 903-911. 10.1016/S0306-4522(98)00489-8.View ArticlePubMedGoogle Scholar
- Sun XM, Soutar AK: Expression in vitro of alternatively spliced variants of the messenger RNA for human apolipoprotein E receptor-2 identified in human tissues by ribonuclease protection assays. Eur J Biochem. 1999, 262 (1): 230-239. 10.1046/j.1432-1327.1999.00394.x.View ArticlePubMedGoogle Scholar
- Carey RM, Balcz BA, Lopez-Coviella I, Slack BE: Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein. BMC Cell Biol. 2005, 6: 30-10.1186/1471-2121-6-30.PubMed CentralView ArticlePubMedGoogle Scholar
- Kaether C, Lammich S, Edbauer D, Ertl M, Rietdorf J, Capell A, Steiner H, Haass C: Presenilin-1 affects trafficking and processing of betaAPP and is targeted in a complex with nicastrin to the plasma membrane. J Cell Biol. 2002, 158 (3): 551-561. 10.1083/jcb.200201123.PubMed CentralView ArticlePubMedGoogle Scholar
- von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM, Spoelgen R, Hshieh TT, Ranganathan S, Battey FD, Liu CX, Bacskai BJ, Sever S, Irizarry MC, Strickland DK, Hyman BT: The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem. 2005, 280 (18): 17777-17785. 10.1074/jbc.M414248200.View ArticlePubMedGoogle Scholar
- Rajendran L, Simons K: Lipid rafts and membrane dynamics. J Cell Sci. 2005, 118 (Pt 6): 1099-1102. 10.1242/jcs.01681.View ArticlePubMedGoogle Scholar
- Huse JT, Pijak DS, Leslie GJ, Lee VM, Doms RW: Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. J Biol Chem. 2000, 275 (43): 33729-33737. 10.1074/jbc.M004175200.View ArticlePubMedGoogle Scholar
- Rechards M, Xia W, Oorschot VM, Selkoe DJ, Klumperman J: Presenilin-1 exists in both pre- and post-Golgi compartments and recycles via COPI-coated membranes. Traffic. 2003, 4 (8): 553-565.View ArticlePubMedGoogle Scholar
- He X, Li F, Chang WP, Tang J: GGA proteins mediate the recycling pathway of memapsin 2 (BACE). J Biol Chem. 2005, 280 (12): 11696-11703. 10.1074/jbc.M411296200.View ArticlePubMedGoogle Scholar
- Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M, Tschape JA, De Strooper B, Muller U, Shen J, Hartmann T: Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol. 2005, 7 (11): 1118-1123.View ArticlePubMedGoogle Scholar
- May P, Bock HH, Nimpf J, Herz J: Differential glycosylation regulates processing of lipoprotein receptors by gamma-secretase. J Biol Chem. 2003, 278 (39): 37386-37392. 10.1074/jbc.M305858200.View ArticlePubMedGoogle Scholar
- Banker GA, Cowan WM: Rat hippocampal neurons in dispersed cell culture. Brain Res. 1977, 126 (3): 397-342. 10.1016/0006-8993(77)90594-7.View ArticlePubMedGoogle Scholar
- Bottenstein JE, Sato GH: Growth of a rat neuroblastoma cell line in serum-free supplemented medium. Proc Natl Acad Sci U S A. 1979, 76 (1): 514-517. 10.1073/pnas.76.1.514.PubMed CentralView ArticlePubMedGoogle Scholar
- Rosso S, Bollati F, Bisbal M, Peretti D, Sumi T, Nakamura T, Quiroga S, Ferreira A, Caceres A: LIMK1 regulates Golgi dynamics, traffic of Golgi-derived vesicles, and process extension in primary cultured neurons. Mol Biol Cell. 2004, 15 (7): 3433-3449. 10.1091/mbc.E03-05-0328.PubMed CentralView ArticlePubMedGoogle Scholar
- Bali PK, Harris WR: Site-specific rate constants for iron removal from diferric transferrin by nitrilotris(methylenephosphonic acid) and pyrophosphate. Arch Biochem Biophys. 1990, 281 (2): 251-256. 10.1016/0003-9861(90)90440-A.View ArticlePubMedGoogle Scholar
- Annaert WG, Esselens C, Baert V, Boeve C, Snellings G, Cupers P, Craessaerts K, De Strooper B: Interaction with telencephalin and the amyloid precursor protein predicts a ring structure for presenilins. Neuron. 2001, 32 (4): 579-589. 10.1016/S0896-6273(01)00512-8.View ArticlePubMedGoogle Scholar
- Wessel D, Flugge UI: A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem. 1984, 138 (1): 141-143. 10.1016/0003-2697(84)90782-6.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.